Thromboembolism and bleeding in patients with atrial fibrillation and liver disease – A nationwide register-based cohort study — Kamilla Steensig (2022) | RDL Network
Thromboembolism and bleeding in patients with atrial fibrillation and liver disease – A nationwide register-based cohort study
Article 2022 en
Authors
KS
Kamilla Steensig
MP
Manan Pareek
AK
Anne Lund Krarup
Abstract
1 min read
Oral anticoagulant initiation in patients with liver disease, incident new atrial fibrillation/flutter, and a high CHA2DS2-VASc-score was associated with a reduced thromboembolism risk. Bleeding risk was not increased with anticoagulation, irrespective of the type of liver disease.
Discussion(0)
No comments yet. Be the first to comment.